Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexbudesonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 13/20 | 0.97 |
| ▸ | PGR | P06401 | 7/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.97 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.97 |
| ▸ | IL5 | P05113 | 1/20 | 0.97 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.97 |
| ▸ | AR | P10275 | 1/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.97 |
| ▸ | MMP9 | P14780 | 1/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.97 |
| ▸ | THPO | P40225 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Budesonide SCHEMBL17168987 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL9763339 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL12440030 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17151422 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL19635 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL13918824 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17971368 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL10020756 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL21570019 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL16139563 | 0.98 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 917 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | AMUNIX PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | claimed |
| CN-104725628-B | A kind of single functionalization branched polyethylene glycol, preparation method and its bio-related substance containing degradable group | 厦门赛诺邦格生物科技股份有限公司 | 2018-04-17 | — | — | CN | claimed |
| EP-1988910-B1 | ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION | KODIAK SCIENCES INC (US) | 2017-12-06 | — | — | EP | claimed |
| CN-104877127-B | A kind of eight arms polyethyleneglycol derivative, preparation method and its bio-related substance of modification | 厦门赛诺邦格生物科技股份有限公司 | 2017-11-10 | — | — | CN | claimed |
| EP-3222142-A1 | ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION | Kodiak Sciences Inc. (US) | 2017-09-27 | — | — | EP | claimed |
| CN-104530413-B | A kind of bio-related substance of multiple functionalized H types polyethyleneglycol derivative modification | 厦门赛诺邦格生物科技股份有限公司 | 2017-08-25 | — | — | CN | claimed |
| CN-104109235-B | A kind of single functionalized poly (ethylene glycol), preparation method and its bio-related substance with nitrogen-atoms branch centers | 厦门赛诺邦格生物科技股份有限公司 | 2017-07-18 | — | — | CN | claimed |
| US-9439862-B2 | Phospholipid-based powders for drug delivery | NOVARTIS AG (CH) | 2016-09-13 | — | — | US | claimed |
| CN-104877127-A | Eight-armed polyethylene glycol derivative, preparation method and related biological substance modified by derivative | XIAMEN SINOPEG BIOTECH CO LTD | 2015-09-02 | — | — | CN | claimed |
| CN-104725628-A | Single functional branched polyethylene glycol containing degradable radical, preparation method and biorelevant substance of single functional branched polyethylene glycol | XIAMEN SINOPEG BIOTECH CO LTD | 2015-06-24 | — | — | CN | claimed |
| CN-104109235-A | Mono-functionalized polyethylene glycol with nitrogen atom branched center and its preparation method and biologically-relevant matter | XIAMEN SINOPEG BIOTECH CO LTD | 2014-10-22 | — | — | CN | claimed |
| US-20140212504-A1 | PHOSPHOLIPID-BASED POWDERS FOR DRUG DELIVERY | NOVARTIS AG (CH) | 2014-07-31 | — | — | US | claimed |
| US-8709484-B2 | Phospholipid-based powders for drug delivery | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | claimed |
| US-20110223216-A1 | Nanoparticles and Porous Particles and Methods of Making the Same | WAYNE STATE UNIVERSITY (US) | 2011-09-15 | — | — | US | claimed |
| US-20100166700-A1 | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates and Their Preparation | OLIGASIS CORPORATION (US) | 2010-07-01 | — | — | US | claimed |
| WO-2010057214-A2 | NANOPARTICLES AND POROUS PARTICLES AND METHODS OF MAKING THE SAME | WAYNE STATE UNIVERSITY (US) | 2010-05-20 | — | — | WO | claimed |
| EP-1988910-A2 | ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION | Oligasis Corporation (US) | 2008-11-12 | — | — | EP | claimed |
| WO-2007100902-A2 | ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION | OLIGASIS CORPORATION (US) | 2007-09-07 | — | — | WO | claimed |
| WO-2007100905-A2 | ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION | NEXGEN THERAPEUTICS, LLC (US) | 2007-09-07 | — | — | WO | claimed |
| EP-1343480-B1 | INDUCED PHASE TRANSITION METHOD FOR THE PRODUCTION OF MICROPARTICLES CONTAINING HYDROPHOBIC ACTIVE AGENTS | ALRISE BIOSYSTEMS GMBH (DE) | 2007-05-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166700-A1 | Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates and Their Preparation | PHOSPHO1, PCTP, SGMS1 | NR3C1 3896/4885PGR 2531/4885CYP3A4 3720/4885 |
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | XPA, TXLNA, NGLY1 | NR3C1 4693/4885PGR 3394/4885CYP3A4 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.